Review of treatment options for Lyme borreliosis

Journal of Chemotherapy

Volumn 17, Issue SUPPL. 2, 2005, Pages 3-16

  Taylor, Rod S ^a   Simpson, I N ^a  

^a Micron Research Ltd   (United Kingdom)

Author keywords

Amoxicillin; Borrelia spp.; Ceftriaxone; Doxycycline; Erythema migrans; Lyme borreliosis; Lyme disease

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; CEFIXIME; CEFODIZIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; EVERNIMICIN; LYME DISEASE VACCINE; MACROLIDE; MEZLOCILLIN; MINOCYCLINE; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TETRACYCLINE DERIVATIVE;

ADJUVANT THERAPY; ANTIMICROBIAL THERAPY; BORRELIA BURGDORFERI; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG PENETRATION; HUMAN; HYPERBARIC OXYGEN; INCIDENCE; INFECTION PREVENTION; LYME DISEASE; PREVENTION; REVIEW; SEROCONVERSION; TICK BORNE DISEASE;

EID: 28044458936     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.supplement-2.3     Document Type: Review

References (87)

1. Steere AC, Malawista SE, Hardin JA, Ruddy S, Askenase W, Andiman WA. Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann Intern Med 1977; 86: 685-698.
2. Sigal LH, Zahradnik JM, Lavin P et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 1998; 339: 216-222.
3. Centers for Disease Control and Prevention (CDC). Lyme Disease. MMWR 2001; 50 (10): 181-185.
4. Schafer C, Hahn M, Oschmann P. Tick ecology and epidemiology. In: Oschmann P, Kraiczy P, Halperin J, Brade V, eds. Lyme Borreliosis and Tick-Borne Encephalitis. Bremen, Germany: UNI-MED, 1999: 30-34.
5. Steere AC. Lyme Disease. N Engl J Med 2001; 345: 115-125.
6. Stanek G, Strle F. Lyme borreliosis. Lancet 2003; 362: 1639-1647.
7. Singh SK, Girschick HJ. Lyme borreliosis: from infection to autoimmunity. Clin Microbiol Infect 2004; 10: 598-614.
8. Franz JK, Krause A. Lyme disease (Lyme borreliosis). Best Pract Res Clin Rheumatol 2003; 17: 241-264.
9. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994; 330: 229-234.
10. Kalish RA, McHugh G, Granquist J, Shae B, Ruthazer R, Steere AC. Persistence of immunoglobin M or immunoglobin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001; 33: 780-785.
11. Dennis DT, Hayes EB, Orloski KA, Meltzer MI. Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999 June 04; 48 (RR07): 1-17.
12. Shapiro ED, Gerber MA. Lyme disease. Clin Infect Dis 2000; 31: 533-542.
13. Pavia CS. Current and novel therapies for Lyme disease. Expert Opin Investig Drugs 2003; 12: 1003-1016.
14. Strle F. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien Klin Wochenschr 1999; 111: 911-915.
15. Steere AC. Lyme disease. N Engl J Med 1989; 321: 586-596.
16. Oschmann P, Kaiser R. Therapy and prognosis. In: Oschmann P, Kraiczy P, Halperin J, Brade V, eds. Lyme Borreliosis and Tick-Borne Encephalitis. Bremen, Germany: UNI-MED, 1999: 112-119.
17. Steere AC, Levin RE, Molloy PJ et al. Treatment of Lyme arthritis. Arthritis Rheum 1994; 37: 878-888.
18. Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clinic Invest 2004; 113: 1093-1101.
19. Brade V, Kraiczy P. Pathogenesis and immune defense. In: Oschmann P, Kraiczy P, Halperin J, Brade V, eds. Lyme Borreliosis and Tick-Borne Encephalitis. Bremen, Germany: UNI-MED, 1999: 42-47.
20. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990; 323: 1438-1444.
21. Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC. Evaluation of study patients with Lyme disease, 10-20 year follow-up. J Infect Dis 2001; 183: 453-460.
22. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. Antimicrob Agents Chemother 1995; 39: 1127-1133.
23. Murgia R, Marchetti F, Cinco M. Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato. Antimicrob Agents Chemother 1999; 43: 3030-3032.
24. Sicklinger M, Wienecke R, Neubert U. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. J Clin Microbiol 2003; 41: 1791-1793.
25. Preac-Mursic V, Wilske B, Schierz G. European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility. Zentralbl Bakteriol Mikrobiol Hyg [A] 1986; 263: 112-118.
26. Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother 1992; 36: 1788-1790.
27. Li M, Masuzawa T, Wang J, Kawabata M, Yanagihara Y. In-vitro and in-vivo antibiotic susceptibilities of Lyme disease Borrelia isolated in China. J Infect Chemother 2000; 6: 65-67.
28. Mursic VP, Wilske B, Schierz G, Holmburger M, Suss E. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 1987; 6: 424-426.
29. Dever LL, Jorgensen JH, Barbour AG. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. Antimicrob Agents Chemother 1993; 37: 1704-1706.
30. Hunfeld KP, Kraiczy P, Wichelhaus TA, Schafer V, Brade V. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int J Antimicrob Agents 2000; 15: 11-17.
31. Johnson RC. Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. Rev Infect Dis 1989; 11 (Suppl 6): S1505-S1510.
32. Johnson RC, Kodner CB, Jurkovich PJ, Collins JJ. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother 1990; 34: 2133-2136.
33. Hansen K, Hovmark A, Lebech AM et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol 1992; 72: 297-300.
34. Johnson RC, Kodner C, Russell M, Girard D. In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin. J Antimicrob Chemother 1990; 25 (Suppl A): 33-38.
35. Cimperman J, Maraspin V, Lotric-Furlan S, Ruzic-Sabljic E, Avsic-Zupanc T, Strle F. Double infection with tick borne encephalitis virus and Borrelia burgdorferi sensu lato. Wien Klin Wochenschr 2002; 114: 620-2.
36. Nadelman RB, Nowakowski J, Fish D et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345: 79-84.
37. Wormser GP, Nadelman RB, Dattwyler RJ et al. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 2000; 31 (Suppl 1): S1-14.
38. Luft BJ, Dattwyler RJ, Johnson RC et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996; 124: 785-791.
39. Luger SW, Paparone P, Wormser GP et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995; 39: 661-667.
40. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992; 117: 273-280.
41. Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 2002; 109: 1173-1177.
42. Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection 2000; 28: 153-156.
43. Wormser GP, Ramanathan R, Nowakowski J et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 697-704.
44. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis - randomised comparison of ceftriaxone and penicillin. Lancet 1988; 1 (8596): 1191-1194.
45. Oksi J, Nikoskelainen J, Viljanen MK. Comparison of oral cefixime and intravenous ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. Eur J Microbiol Infect Dis 1998; 17: 715-719.
46. Dattwyler RJ, Luft BJ, Kunkel MJ et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 1997; 337: 289-294.
47. Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999; 180: 377-383.
48. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 1994; 44: 1203-1207.
49. Karkkonen K, Stiernstedt SH, Karlsson M. Follow-up of patients treated with oral doxycycline for Lyme neuroborreliosis. Scand J Infect Dis 2001; 33: 259-262.
50. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J. Ceftriaxone in the treatment of Lyme neuroborreliosis. Infection 1996; 24: 88-90.
51. Wahlberg P, Granlund H, Nyman D, Panelius J, Seppala I. Treatment of late Lyme borreliosis. J Infect 1994; 29: 255-261.
52. Kaiser R. Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone. Nervenarzt 2004; 75: 553-557.
53. Bloom BJ, Wyckoff PM, Meissner HC, Steere AC. Neurocognitive abnormalities in children after classic manifestations of Lyme disease. Pediatr Infect Dis J 1998; 17: 189-196.
54. Vázquez M, Sparrow SS, Shapiro ED. Long-term neuropsychologic and health outcomes of children with facial nerve palsy attributable to Lyme disease. Pediatrics 2003; 112: e93-e97.
55. Suttorp-Schulten MS, Kuiper H, Kijlstra A, van Dam AP, Rothova A. Long-term effects of ceftriaxone treatment on intraocular Lyme borreliosis. Am J Ophthalmol 1993; 116: 571-575.
56. Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol 1995; 32 (2 Pt 1): 223-227.
57. Smilack JD. The tetracyclines. Mayo Clin Proc 1999; 74: 727-729.
58. Hengge UR, Tannapfel A, Tyring SK, Erbel R, Arendt G, Ruzicka T. Lyme borreliosis. Lancet Infect Dis 2003; 3: 489-500.
59. Donta ST. Macrolide therapy of chronic Lyme Disease. Med Sci Monit 2003; 9: PI136-142.
60. Wormser GP. Lyme disease: insights into the use of antimicrobials for prevention and treatment in the context of experience with other spirochetal infections. Mt Sinai J Med 1995; 62: 188-195.
61. Jaruratanasirikul S, Hortiwakul R, Tantisarasart T, Phuenpathom N, Tussanasunthornwong S. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother 1996; 40: 825-826.
62. Verdon ME, Sigal LH. Recognition and management of Lyme disease. Am Fam Physician 1997; 56: 427-436, 439-440.
63. Nowakowski J, McKenna D, Nadelman RB et al. Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 2000; 9: 563-567.
64. Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991; 163: 311-318.
65. Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs 2002; 62: 1041-1089.
66. Eppes SC. Diagnosis, treatment, and prevention of Lyme disease in children. Paediatr Drugs 2003; 5: 363-372.
67. Dattwyler RJ, Halperin JJ, Pass H, Luft BJ. Ceftriaxone as effective therapy in refractory Lyme disease. J Infect Dis 1987; 155: 1322-1325.
68. Luft BJ, Volkman DJ, Halperin JJ, Dattwyler RJ. New chemotherapeutic approaches to the treatment of Lyme borreliosis. Ann N Y Acad Sci 1988; 539: 352-361.
69. Hassler D, Zoller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG. Cefotaxime versus penicillin in the late stage of Lyme disease - prospective, randomized therapeutic study. Infection 1990; 18: 16-20.
70. Halperin JJ. Neuroborreliosis (Nervous System Lyme Disease). Curr Treat Options Neurol 1999; 1: 139-146.
71. Levin JM, Nelson JA, Segreti J, Harrison B, Benson CA, Strle F. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother 1993; 37: 1444-1446.
72. Lakos A, Nagy G. Effect of an antibiotic combination on the propagation of Borrelia burgdorferi, causative agent of Lyme disease. Orv Hetil 1999; 140: 1529-1532.
73. Pavia CS, Wormser GP, Nowakowski J, Cacciapuoti A. Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease. Antimicrob Agents Chemother 2001; 45: 936-937.
74. Klempner MS, Hu LT, Evans J et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85-92.
75. National Institute of Neurological Disorders and Stroke (NINDS). Clinical Study Protocol Number R01NS38636. PET and MRI imaging of persistent Lyme encephalopathy. http://www.clinicaltrials.gov/ct/gui/show/NCT00037479?order=2 (accessed 18 August 2004).
76. National Institute of Allergy and Infectious Diseases (NIAID). Clinical Study Protocol Number 96-I-0052: A comprehensive clinical, microbiological and immunological assessment of patients with suspected chronic Lyme infection and selected control populations. http://www.clinicaltrials.gov/ct/gui/show/ NCT00001539?order=3 (accessed 18 Aug 2004).
77. National Institute of Allergy and Infectious Diseases (NIAID). Clinical Study Protocol Number 02-I-0055: Evaluation, treatment and follow-up of patients with Lyme disease. http://www.clinicaltrials.gov/ct/gui/show/NCT00028080?order= 1 (accessed 18 August 2004).
78. Steere AC, Sikand VK, Meurice F et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 1998; 339: 209-215.
79. Ridoloxan Plus product information. Aloha Medicinals Inc., Hailu, HI, USA. http://alohamedicinals.com/lyme-aid.htm (accessed 18 August 2004).
80. Eppes SC, Klein JD, Caputo GM, Rose CD. Physician beliefs, attitudes, and approaches toward Lyme disease in an endemic area. Clin Pediatr (Phila) 1994; 33: 130-134.
81. Sigal LH. The Lyme disease controversy. Social and financial costs of misdiagnosis and mismanagement. Arch Intern Med 1996; 156: 1493-1500.
82. Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998; 128: 354-362.
83. Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States. Clin Ther 1998; 20: 993-1008.
84. Adu A, Armour CL. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Drugs 1995; 50: 423-439.
85. Hotchkies L, Grima DT, Hedayati S. The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost. Clin Ther 1996; 18: 716-725.
86. Stanek G, Kahl O. Chemoprophylaxis for Lyme borreliosis? Zentralbl Bakteriol 1999; 289: 655-665.
87. Strle F, Nadelman RB, Cimperman J et al. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med 1999; 130: 32-36.